Tectonic Therapeutic Inc (TECX)
NASDAQ:TECX
Want to see TECX full AI Analyst Report?
TECX Stock Chart & Stats
$29.51
-$0.66(-1.42%)
At close: 4:00 PM EST
$29.51
-$0.66(-1.42%)
Day’s Range― - ―
52-Week Range$14.39 - $36.03
Previous CloseN/A
Volume30.18K
Average Volume (3M)201.59K
Market Cap
$572.49M
Enterprise Value$334.95M
Total Cash (Recent Filing)$236.89M
Total Debt (Recent Filing)$4.63M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 19, 2026EPS Estimate
-1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.46
Shares Outstanding18,869,186
10 Day Avg. Volume127,991
30 Day Avg. Volume201,586
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.16
Forecast
1Y Price Target
$80.75Price Target Upside173.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthTectonic carries very low leverage with minimal debt versus a sizable equity and asset base, providing durable financial flexibility. This reduces near-term solvency risk and supports funding clinical programs or strategic deals without immediate distress financing, preserving optionality.
Advancing Lead Clinical ProgramCompletion of enrollment in the global Phase 2 APEX trial is a structural milestone that de-risks timeline uncertainty and creates a clear binary catalyst (topline Q1 2027). A positive readout could validate the platform, enable partnerships, and materially alter commercialization prospects.
Board Strengthens Capital Markets ExpertiseAdding an experienced healthcare investment banker to the board materially strengthens access to capital and M&A execution capabilities. This durable governance improvement can improve fundraising options, strategic transactions, and credibility with investors as development needs continue.
Bears Say
Pre-revenue Business ModelTectonic remains pre-revenue, meaning its long-term value depends entirely on successful development and commercialization of pipeline candidates. Without product revenues, the company must continually finance operations, leaving future cash flows uncertain until commercial milestones are achieved.
Accelerating Net LossesLosses have widened materially over time, reflecting ramping R&D and operating expenses. Persistently expanding deficits increase the probability of further equity dilution or onerous financing terms, and they can erode the current equity buffer if development timelines slip.
Persistent Negative Cash Flow / BurnOperating cash flow and free cash flow are deeply negative and worsening, forcing reliance on external capital. This structural cash burn constrains strategic flexibility, may limit ability to fund multiple programs, and elevates execution risk if capital markets tighten or trial outcomes delay.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic Inc’s price range in the past 12 months?
Tectonic Therapeutic Inc lowest stock price was $14.38 and its highest was $36.03 in the past 12 months.
What is Tectonic Therapeutic Inc’s market cap?
Tectonic Therapeutic Inc’s market cap is $572.49M.
When is Tectonic Therapeutic Inc’s upcoming earnings report date?
Tectonic Therapeutic Inc’s upcoming earnings report date is Aug 19, 2026 which is in 56 days.
How were Tectonic Therapeutic Inc’s earnings last quarter?
Tectonic Therapeutic Inc released its earnings results on May 07, 2026. The company reported -$1.34 earnings per share for the quarter, missing the consensus estimate of -$1.165 by -$0.175.
Is Tectonic Therapeutic Inc overvalued?
According to Wall Street analysts Tectonic Therapeutic Inc’s price is currently Undervalued.
Does Tectonic Therapeutic Inc pay dividends?
Tectonic Therapeutic Inc does not currently pay dividends.
What is Tectonic Therapeutic Inc’s EPS estimate?
Tectonic Therapeutic Inc’s EPS estimate is -1.35.
How many shares outstanding does Tectonic Therapeutic Inc have?
Tectonic Therapeutic Inc has 18,869,186 shares outstanding.
What happened to Tectonic Therapeutic Inc’s price movement after its last earnings report?
Tectonic Therapeutic Inc reported an EPS of -$1.34 in its last earnings report, missing expectations of -$1.165. Following the earnings report the stock price went up 7.927%.
Which hedge fund is a major shareholder of Tectonic Therapeutic Inc?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.75 (173.64% Upside)
$80.75 (173.64% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 395.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.15%
12-Months-Change
Fundamentals
Return on Equity
-32.33%
Trailing 12-Months
Asset Growth
-21.68%
Trailing 12-Months
Company Description
Tectonic Therapeutic Inc
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$80.75
▲(173.64% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
35.62% Insiders
15.04% Mutual Funds
31.66% Other Institutional Investors
11.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---